Orexin B (also known in research literature as Hypocretin-2) from Super Human Peptides UK is a highly conserved, naturally occurring 28-amino acid neuropeptide. Endogenously, it is produced exclusively by a small cluster of specialized neurons located in the lateral hypothalamus. In laboratory research, Orexin B is the premier model for investigating the neurological control of arousal, wakefulness, and energy homeostasis.
While its sister peptide (Orexin A) binds equally to both orexin receptors, researchers utilize Orexin B specifically because it exhibits a highly selective, massive binding affinity for the Orexin Type 2 Receptor (OX2R). This OX2R pathway is directly responsible for maintaining the sleep-wake cycle and preventing the sudden transition into REM sleep. Produced under GMP-compliant conditions and verified for 99% purity or higher, Orexin B is an essential preclinical tool for advanced research into narcolepsy, cataplexy, severe sleep disorders, and complex reward-pathway mapping.
- —Hypothalamic Neuropeptide: Models the exact endogenous sequence responsible for systemic arousal and metabolic regulation.
- —OX2R Specificity: Highly selective agonist for the Orexin Type 2 Receptor, distinguishing its effects from Orexin A.
- —Sleep-Wake Regulator: The primary peptide pathway studied for the maintenance of wakefulness and the prevention of narcolepsy.
- —Rapid Pharmacokinetics: Exhibits a naturally shorter half-life than Orexin A, allowing for highly controlled, acute receptor activation studies.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Narcolepsy Models: Preclinical investigation into the exact pathophysiology of narcolepsy and cataplexy following the knockout or degradation of orexin-producing neurons.
- —OX2R Receptor Kinetics: Studying the highly specific intracellular signaling cascades triggered when Orexin B binds to the Type 2 receptor, bypassing OX1R pathways.
- —Arousal and Vigilance: Measuring the rapid pharmacological induction of wakefulness and enhanced locomotor activity in sleep-deprived animal models.
- —Energy Homeostasis: Investigating the peptide's role as an "orexigenic" (appetite-stimulating) factor that ties caloric demand directly to states of physical arousal.
- —Addiction and Reward: Researching how lateral hypothalamic orexin projections interact with the ventral tegmental area (VTA) to modulate dopamine release and drug-seeking behavior.
Orexins were discovered simultaneously in 1998 by two independent research teams (Sakurai et al., who named them Orexins for their role in appetite, and de Lecea et al., who named them Hypocretins for their hypothalamic origins).
Laboratory studies mapping the orexin system yielded one of the most significant neurological discoveries of the decade: the absolute dependency of the sleep-wake cycle on Orexin B and the OX2 receptor. In landmark animal studies, subjects genetically engineered to lack the OX2 receptor exhibited severe narcolepsy and sudden cataplexy (loss of muscle tone), completely unable to maintain a consolidated state of wakefulness. By administering synthetic Orexin B, researchers can study the rapid, dose-dependent rescue of this neurological deficit.
Because it acts as the "master switch" for consciousness and energy expenditure, it remains a heavily prioritized compound in modern neuropharmacology.
- 1.Sakurai, T. et al., "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior," Cell, 1998.
- 2.Chemelli, R.M. et al., "Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation," Cell, 1999.
- 3.Willie, J.T. et al., "To eat or to sleep? Orexin in the regulation of feeding and wakefulness," Annual Review of Neuroscience, 2001.
- 4.Gotter, A.L. et al., "Orexin receptors as therapeutic drug targets," Progress in Brain Research, 2012.
